Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations. Issue 2 (13th May 2014)

• Record Type: Journal Article
• Authors: Nambiar, S; Laessig, K; Toerner, J; Farley, J; Cox, E
• Is Part Of: Clinical pharmacology & therapeutics. Volume 96:Issue 2(2014)
• Page Start: 147
• Page End: 149
• Publication Date: 2014-05-13
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1038/clpt.2014.116
• Languages: English
• ISSNs: 0009-9236

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>A decline in antibacterial drug development coupled with emerging bacterial resistance has resulted in limited treatment options. One of the challenges facing antibacterial drug development is appropriate clinical trial designs. Noninferiority trials are appropriate to study new antibacterial drugs for the treatment of serious diseases; superiority trials can be challenging and cannot be the only acceptable trial design to study antibacterial drugs. Our efforts must continue to make new therapies available to meet patient needs.</p> <p> <italic>Clinical Pharmacology &amp; Therapeutics</italic> (2014); <bold>96</bold> 2, 147–149. doi:<ext-link ext-link-type="doi" xlink:type="simple" xmlns:xlink="http://www.w3.org/1999/xlink">10.1038/clpt.2014.116</ext-link></p> </abstract>